Working Out Which Therapy is Best for Treating Metastatic Cancer
Credit: Baylor College of Medicine
A new laboratory technique developed by researchers at Baylor College of Medicine and other institutions can rapidly test the effectiveness of treatments for life-threatening breast cancer metastases in bone. The study appears in Nature Communications.
“For a number of breast cancer patients, the problem is metastasis – the dissemination of breast tumor cells to other organs – after the primary tumor has been eliminated,” said corresponding author Dr. Xiang Zhang, associate professor of molecular and cellular biology and the Lester and Sue Smith Breast Center at Baylor. “Metastases, however, tend to respond differently than the primary tumor to the treatment in part due to residing in a different organ with a different microenvironment.”
Until now, there has not been an effective experimental platform to study metastatic tumors in their new microenvironment.
“We have created an experimental system in which we can mimic the interactions between cancer cells and bone cells, as bone is the place where breast cancer, and many other cancers too, disseminates most frequently,” said Zhang, who also is a McNair Scholar at Baylor. “We have developed a system that allows us to test many different drug responses simultaneously to discover the therapy that can selectively act on metastatic cancer cells and minimize the effect on the bone.”
Bone-in culture array
To mimic the interactions between metastatic breast cancer cells and bone cells in a living system in the lab, Zhang and his colleagues developed a bone metastasis model, called bone-in culture array, by fragmenting mouse bones that already contain breast cancer cells.
The scientists determined that the bone-in culture maintains the microenvironmental characteristics of bone metastasis in living animal models, and the cancer cells maintain the gene expression profile, the growth pattern and their response to therapies.
Using the bone-in model, the researchers determined that the drug danusertib preferentially inhibits bone metastasis. They also found that other drugs stimulate the growth of slow-growing cancer cells in the bone.
In addition to determining the effect of drugs in the growth of metastasis in bone, the bone-in culture can be used to investigate mechanisms involved in bone colonization by cancer cells.
Implications for cancer treatment
“We think that this new system has the potential to be applied not only to breast cancer but to other cancers that also metastasize to the bone,” Zhang said. “This technique can be scaled up to larger sample sizes, which would help accelerate the process of discovering metastatic cancer treatments. We have already found a few interesting drugs. We will keep looking for more and focus on those that are most promising.”
In the future, the scientists expect to develop this platform into a standardized system that can be used in the clinic to find specific drugs that can better treat metastatic cancer.
This article has been republished from materials provided by Baylor College of Medicine. Note: material may have been edited for length and content. For further information, please contact the cited source.
Wang, H., Tian, L., Goldstein, A., Liu, J., Lo, H., Sheng, K., . . . Zhang, X. H. (2017). Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies. Nature Communications, 8, 15045. doi:10.1038/ncomms15045
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Synpromics Announces Gene Therapy Research Partnership with Solid BiosciencesNews
Synpromics partner with Solid Biosciences ro develop treatment options Duchenne muscular dystrophy.READ MORE
Agilent Announces Expanded Use of Cancer Diagnostic in the USNews
Agilent announced that the FDA has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma (UC) and of squamous cell carcinoma of the head and neck (SCCHN).READ MORE
Comments | 0 ADD COMMENT
9th International conference on Tissue Engineering and Regenerative Medicine
Nov 09 - Nov 10, 2018
International Conference & Exhibition on Tissue Engineering and Biobanking
Apr 23 - Apr 24, 2018